TITLE

DANISH BIOTECH PIPELINE RANKS THIRD IN EUROPE

PUB. DATE
January 2009
SOURCE
Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Denmark ranks third in the European biotechnology market, according to the findings of the 2008 Ernst & Young report "Biotech in Denmark 2008--Growing Stronger." The report's findings also indicated that Denmark has a strong position in terms of pipeline growth among the countries in Europe and the preparedness of the Copenhagen Region for future challenges. Also noted is the strong pipeline development in the preclinical and clinical sectors.
ACCESSION #
35859765

 

Related Articles

  • Biotech companies' comeback. LaFemina, Lorraine // Long Island Business News (7/1993 to 5/2009);6/10/96, Vol. 43 Issue 24, p1 

    Reports on the financial recovery of biotech companies in Long Island, New York as indicated by a report by Ernst & Young LLP. Product sales and revenues in 1996; Number of biotech workers in Long Island; Comments of Barry Winer of Enzo.

  • Biotech Firms Are Growing More Profitable. Payne, Scott // Grand Rapids Business Journal;10/22/2001, Vol. 19 Issue 43, p18 

    Focuses on the growing profitability of biotechnology firms, according to a study conducted by Ernst & Young LLP. Rise in the number of biotechnology firms; Growth in industry employment; Increase in the number of drug approvals.

  • Biotech industry faces financing gap.  // R&D Magazine;May99, Vol. 41 Issue 6, p7 

    Presents an update on the public financing markets for the biotechnology industry, according to Ernest & Young's report. Decline of equity financing in 1998; Factors for the financing gap.

  • Biotechnology poised for profitability.  // Westchester County Business Journal;7/7/2003, Vol. 42 Issue 27, p26 

    Reports on the outlook of global biotechnology industry in 2003 according to Ernst & Young in the U.S. Total number of biotech companies continuing to grow; Forecasts of profitability by 2010 if regulatory and reimbursement issues can be dealt with; List of the critical drivers furthering the...

  • A Shrinking Marketplace. Dickey, Chris // Drug Discovery & Development;Jul2003, Vol. 6 Issue 7, p11 

    Editorial. Comments on Ernst & Young's survival index of publicly traded biotechnology companies. Data showing that the biotechnology market will shrink by 30 percent; Reputation of the industry for innovation; Novel approaches as a central requirement to speed delivery of new therapies.

  • Australian biotech sector grew 7% in 2012.  // Australian Life Scientist;Jul/Aug2013, Vol. 10 Issue 4, p6 

    The article focuses on the Biotechnology Industry Report issued by the professional services company Ernst and Young LLP which stated that the biotechnology industry of Australia has increased by seven percent in 2012.

  • Europe's biotech industry still losing to US, say analysts. Schiermeier, Quirin // Nature;5/24/2001, Vol. 411 Issue 6836, p404 

    Reports on the performance of the biotechnology industry in Europe according to a report issued by the Ernst & Young company. Initial public offering performance of biotechnology companies in Europe; Advantages of biotechnology companies in the United States over their European counterparts;...

  • Biotech Industry Could Face Major Shakeout.  // Chemical Market Reporter;6/17/2002, Vol. 261 Issue 24, p6 

    Reports on the potential shakeout facing the European biotechnology industry according to Ernst & Young Incorporated. Reason for the industry's need to engage in merger and acquisition activity; Worth of investment funds attracted by the industry in 2001.

  • Biotech ready for breakthrough.  // R&D Magazine;Jun98, Vol. 40 Issue 7, p9 

    States that a report issued by Ernst and Young LLP predicted that the biotechnology industry in the United States will break-even by the year 2000. Reasons for the predictions made.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics